274 related articles for article (PubMed ID: 32493453)
1. Cerebrospinal fluid penetration of targeted therapeutics in pediatric brain tumor patients.
Guntner AS; Peyrl A; Mayr L; Englinger B; Berger W; Slavc I; Buchberger W; Gojo J
Acta Neuropathol Commun; 2020 Jun; 8(1):78. PubMed ID: 32493453
[TBL] [Abstract][Full Text] [Related]
2. A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder.
Callegari E; Malhotra B; Bungay PJ; Webster R; Fenner KS; Kempshall S; LaPerle JL; Michel MC; Kay GG
Br J Clin Pharmacol; 2011 Aug; 72(2):235-46. PubMed ID: 21392072
[TBL] [Abstract][Full Text] [Related]
3. Central Nervous System Distribution of Panobinostat in Preclinical Models to Guide Dosing for Pediatric Brain Tumors.
Zhang W; Oh JH; Zhang W; Rathi S; Larson JD; Wechsler-Reya RJ; Sirianni RW; Elmquist WF
J Pharmacol Exp Ther; 2023 Dec; 387(3):315-327. PubMed ID: 37827699
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic considerations in the treatment of CNS tumours.
Motl S; Zhuang Y; Waters CM; Stewart CF
Clin Pharmacokinet; 2006; 45(9):871-903. PubMed ID: 16928151
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of antibacterial agents in the CSF of children and adolescents.
Sullins AK; Abdel-Rahman SM
Paediatr Drugs; 2013 Apr; 15(2):93-117. PubMed ID: 23529866
[TBL] [Abstract][Full Text] [Related]
6. Topotecan central nervous system penetration is altered by a tyrosine kinase inhibitor.
Zhuang Y; Fraga CH; Hubbard KE; Hagedorn N; Panetta JC; Waters CM; Stewart CF
Cancer Res; 2006 Dec; 66(23):11305-13. PubMed ID: 17145877
[TBL] [Abstract][Full Text] [Related]
7. The influence of the coadministration of the p-glycoprotein modulator elacridar on the pharmacokinetics of lapatinib and its distribution in the brain and cerebrospinal fluid.
Karbownik A; Sobańska K; Płotek W; Grabowski T; Klupczynska A; Plewa S; Grześkowiak E; Szałek E
Invest New Drugs; 2020 Jun; 38(3):574-583. PubMed ID: 31177402
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy delivery issues in central nervous system malignancy: a reality check.
Muldoon LL; Soussain C; Jahnke K; Johanson C; Siegal T; Smith QR; Hall WA; Hynynen K; Senter PD; Peereboom DM; Neuwelt EA
J Clin Oncol; 2007 Jun; 25(16):2295-305. PubMed ID: 17538176
[TBL] [Abstract][Full Text] [Related]
9. Strategies for increasing drug delivery to the brain: focus on brain lymphoma.
Siegal T; Zylber-Katz E
Clin Pharmacokinet; 2002; 41(3):171-86. PubMed ID: 11929318
[TBL] [Abstract][Full Text] [Related]
10. Central nervous system pharmacokinetics of the Mdr1 P-glycoprotein substrate CP-615,003: intersite differences and implications for human receptor occupancy projections from cerebrospinal fluid exposures.
Venkatakrishnan K; Tseng E; Nelson FR; Rollema H; French JL; Kaplan IV; Horner WE; Gibbs MA
Drug Metab Dispos; 2007 Aug; 35(8):1341-9. PubMed ID: 17470526
[TBL] [Abstract][Full Text] [Related]
11. ATP-binding cassette transporters restrict drug delivery and efficacy against brain tumors even when blood-brain barrier integrity is lost.
de Gooijer MC; Kemper EM; Buil LCM; Çitirikkaya CH; Buckle T; Beijnen JH; van Tellingen O
Cell Rep Med; 2021 Jan; 2(1):100184. PubMed ID: 33521698
[TBL] [Abstract][Full Text] [Related]
12. A Practical Perspective on the Evaluation of Small Molecule CNS Penetration in Drug Discovery.
Huang L; Wells MC; Zhao Z
Drug Metab Lett; 2019; 13(2):78-94. PubMed ID: 30854983
[TBL] [Abstract][Full Text] [Related]
13. Quantitative evaluation of the impact of active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as a surrogate.
Kodaira H; Kusuhara H; Fujita T; Ushiki J; Fuse E; Sugiyama Y
J Pharmacol Exp Ther; 2011 Dec; 339(3):935-44. PubMed ID: 21934030
[TBL] [Abstract][Full Text] [Related]
14. Barriers to Effective Drug Treatment for Brain Metastases: A Multifactorial Problem in the Delivery of Precision Medicine.
Kim M; Kizilbash SH; Laramy JK; Gampa G; Parrish KE; Sarkaria JN; Elmquist WF
Pharm Res; 2018 Jul; 35(9):177. PubMed ID: 30003344
[TBL] [Abstract][Full Text] [Related]
15. Blood-brain barrier permeation and efflux exclusion of anticholinergics used in the treatment of overactive bladder.
Chancellor MB; Staskin DR; Kay GG; Sandage BW; Oefelein MG; Tsao JW
Drugs Aging; 2012 Apr; 29(4):259-73. PubMed ID: 22390261
[TBL] [Abstract][Full Text] [Related]
16. Cerebrospinal fluid concentrations of gefitinib in patients with lung adenocarcinoma.
Zhao J; Chen M; Zhong W; Zhang L; Li L; Xiao Y; Nie L; Hu P; Wang M
Clin Lung Cancer; 2013 Mar; 14(2):188-93. PubMed ID: 22846582
[TBL] [Abstract][Full Text] [Related]
17. Development of an UPLC-MS/MS method for quantification of Avitinib (AC0010) and its five metabolites in human cerebrospinal fluid: Application to a study of the blood-brain barrier penetration rate of non-small cell lung cancer patients.
Wang W; Zheng X; Wang H; Wang L; Jiang J; Hu P
J Pharm Biomed Anal; 2017 May; 139():205-214. PubMed ID: 28285073
[TBL] [Abstract][Full Text] [Related]
18. Overcoming the blood-brain barrier in chemotherapy treatment of pediatric brain tumors.
Wu L; Li X; Janagam DR; Lowe TL
Pharm Res; 2014 Mar; 31(3):531-40. PubMed ID: 23996470
[TBL] [Abstract][Full Text] [Related]
19. Quantitative and Mechanistic Understanding of AZD1775 Penetration across Human Blood-Brain Barrier in Glioblastoma Patients Using an IVIVE-PBPK Modeling Approach.
Li J; Wu J; Bao X; Honea N; Xie Y; Kim S; Sparreboom A; Sanai N
Clin Cancer Res; 2017 Dec; 23(24):7454-7466. PubMed ID: 28928160
[No Abstract] [Full Text] [Related]
20. Cerebrospinal fluid penetration of the colony-stimulating factor-1 receptor (CSF-1R) inhibitor, pexidartinib.
Shankarappa PS; Peer CJ; Odabas A; McCully CL; Garcia RC; Figg WD; Warren KE
Cancer Chemother Pharmacol; 2020 May; 85(5):1003-1007. PubMed ID: 32306101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
